These findings reinforce the functional relevance of CK2 in mediating resistance to BRAF inhibition and support the rationale for incorporating CK2-targeted approaches in therapeutic regimens aimed at improving clinical outcomes in patients with BRAF melanoma. The gene discussed is BRAF; the disease is melanoma.